David Mitchell, president and founder of Patients for Affordable Drugs, discusses the importance of reducing out-of-pocket costs and premiums for patients, the need for an entity to recommend costs for novel therapies to payers, pieces of legislation that address drug patent “abuse” on the part of manufacturers, and more.
David is an amazing inspiring patient advocate. He is a myeloma patients but understands the danger of exponentially expensive drug prices. Listen to what he does and how he has impacted patient care delivery.
Dr Nabhan and the podcast guests have no relevant financial disclosures.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
